Published in final edited form as:

Tetrahedron Lett. 2012 October 24; 53(43): 5787–5790. doi:10.1016/j.tetlet.2012.08.072.

A Van Leusen deprotection-cyclization strategy as a fast entry into two imidazoquinoxaline families

Fabio De Moliner^a and Christopher Hulme^{a,b,*}

^aDepartment of Pharmacology and Toxicology, College of Pharmacy, BIO5 Oro Valley, The University of Arizona, 1580 E. Hanley Blvd., Oro Valley, Arizona 85737, USA

^bDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, USA

Abstract

A concise synthesis of two pharmacologically relevant classes of molecules possessing the imidazoquinoxaline core is reported. The protocol involves use of 1,2-phenylenediamines and glyoxylic acid derivatives, namely ethyl glyoxylate or benzylglyoxamide, along with tosylmethylisocyanides in a microwave-assisted Van Leusen three-component condensation. Subsequent unmasking (Boc removal) of an internal amino-nucleophile promotes deprotection and cyclization that take place either spontaneously in a one-pot fashion to give **8** or upon acidic treatment under microwave irradiation after isolation of the imidazole intermediate to give **11**. Of note, a tricyclic framework is hence assembled by means of a rapid and straightforward method with a high bond-forming efficiency.

Keywords

TOSMICs; Multicomponent reactions; Heterocycles; Imidazoquinoxalines

Tosylmethylisocyanides (TOSMICs) are a valuable and versatile class of synthons that are growing increasingly popular in the organic chemistry community. In addition to the isonitrile functional group, a well-known multi-purpose synthetic tool, TOSMICs also display two more reactive features:¹ namely, these molecules are endowed with a tosyl residue that can easily act as a leaving group,² and with an activated methylene they are prone to attack electrophiles upon deprotonation. Thanks to their peculiar nature, TOSMICs have been fruitfully employed in the preparation of several families of heterocycles, such as oxazoles,³ pyrroles,⁴ imidazoles,⁵ benzofuranes,⁶ quinoxalines,⁷ and pyrrolopyrimidines.⁸ Unsurprisingly, within this diversified panel of synthetic strategies multicomponent- based approaches stand out as a recurrent theme. In fact, multicomponent reactions (MCRs) represent an extremely powerful tool for the generation of a high level of molecular diversity and for the expeditious assembly of complex molecular frameworks in an efficient, straightforward, and facile manner.⁹ In this context, the Van Leusen three-component reaction (V-3CR)² exemplifies a perfect combination between the operational ease and exploratory power of MCRs and the multiple reactivities of TOSMICs, resulting in a process that generates a medicinally relevant imidazole nucleus¹⁰ upon a cascade mechanism triggered by nucleophilic attack onto a preformed Schiff base (Scheme 1). As proof of its importance, numerous reports describing its use to prepare biologically active compounds

are available in the literature,¹¹ and extensive studies have been dedicated to further elaboration of its products¹² by means of post-condensation modifications, according to a *modus operandi* that is quite common in the MCR field.¹³ Furthermore, a highly elegant MCR for the synthesis of imidazolines¹⁴ has been developed from the V-3CR by Orru via the replacement of the TOSMICs with different α -acidic isocyanides. This merely reflects that this transformation constitutes a very fertile background for the development of more enabling novel chemical methodologies.

As a part of our endeavor to design novel general and succinct multicomponent-based routes that enable fast access to drug-like chemotypes in an operationally-friendly way,¹⁵ we recently turned our attention to the enticing scenarios unveiled by coupling the Van Leusen imidazole synthesis with a post-condensation modification triggered by the unmasking of an internal nucleophile.¹⁶ By choosing ethyl glyoxylate and benzyl glyoxamide as the carbonyl inputs and *N*-Boc 1,2-phenylenediamines as the amine building blocks, two diverse imidazoquinoline-based scaffolds were readily synthesized. The new methodologies represent enticing enhancements to the V-3CR reactivity domain, delivering tricyclic chemotypes that will be of high interest in the drug discovery arena.

Initially, ethyl glyoxylate was examined as a partner in the MCR pathway (Table 1). Based on our previous experience in this field,¹⁶ DMF was evaluated as the solvent for both the Schiff base preformation, which is required for the Van Leusen reaction,⁹ and the second, base-promoted step under microwave irradiation conditions. Gratifyingly, short cycle times turned out to be optimal for both steps, and when intermediate **6** was combined with TOSMIC **7** and potassium carbonate and subjected to elevated temperatures, a one-pot multi-component condensation, Boc-deprotection, and cyclization rendered **8a**. Optimal conditions were found to be microwave irradiation at 100 °C for 10 min for step A, followed by further irradiation at 180 °C for 10 min, which pushed the process to completion after the addition of isonitrile and base (entry 4).¹⁷ A good overall yield (47% isolated in **8a**) was observed under these conditions.

Encouraged by this result, a small collection of seven imidazo[1,5-*a*]quinoxalinones (Fig. 1) were thus prepared by means of the optimized methodology employing a diversity-enhancing set of four *N*-Boc 1,2-phenylenediamines and three TOSMICs. All proceeded smoothly, affording the expected products in yields ranging from 27% to 47%, representing a good level of efficiency in light of the number of transformations embedded in this pathway. As regards to the scope, it turned out to be quite general for the amine input, while TOSMICs with R₃ = Aryl were found to be incompatible where only complex mixtures of side products being observed.

Having developed a new expeditious route into a medicinally relevant tricyclic scaffold, which has been reported to be the key feature in molecules active against a number of pathologies such as cancer, arthritis, and erectile dysfunction,¹⁸ we envisaged that introduction of an exocyclic amino group would be pivotal in generating one more pharmacologically active chemotype. In fact, imidazo[1,5-*a*]quinoxalines displaying such a substituent are known to exert inhibition of important members of the tyrosine kinase family.¹⁹ Additionally, the required use of glyoxamides in this strategy represents employment of a novel reagent in the V-3CR. Although scarce commercial availability and synthetic accessibility impeded evaluation of different amide inputs, benzylglyoxamide could be readily obtained from the corresponding tartaric acid amide by means of treatment with periodic acid according to a reported procedure.²⁰ However, in this case, (Table 2) irradiating at temperatures above 140 °C (entries 1 and 2, step B) afforded no observable product, while milder conditions proved beneficial (entry 7) even though only imidazole intermediate **10a** was recovered and tricyclic product could not be formed in a one-pot

fashion. In regards to Schiff base formation (step A), heating at 100 °C for 10 min again proved optimal.

With a proficient route²¹ to **10a** in hand, simple dissolution in a 10% TFA solution in DCE at room temperature promoted cyclization, and unexpectedly debenzylation in one pot afforded **11a**. Upon further screening (Table 3) this behavior was found to be reproducible under microwave irradiation, and **11a** was constantly recovered in high yield, with optimal conditions shown in entry 5.²²

To the best of our knowledge, removal of a benzyl residue in acidic conditions is unprecedented in the primary literature. From a biological perspective, this deprotection was highly encouraging, as imidazoquinoxalines bearing a primary amino group have been shown to target phosphodiesterases and adenosine receptors.²³

The two-step pathway was subsequently used to synthesize seven examples. Four 1,2-phenylenediamines and six TOSMICs were successfully explored in the Van Leusen reaction along with benzylglyoxamide, giving desired products in good yields ranging from 52% to 83% (Fig. 2). Subsequent acid-induced deprotection–cyclization proceeded smoothly, and **11a–11g** were obtained in excellent 84–99% yields in a very clean manner that required no purification, with the only loss of material due to the aqueous work-up. Of note, when heterocyclic diamines having a pyridine or pyrimidine core were evaluated, the Van Leusen reaction performed poorly (<15% yield) and no tricyclic products **11** were observed, even under prolonged irradiation.

In conclusion, we have herein reported a straightforward MCR-based methodology exploiting the Van Leusen three-component reaction (V-3CR) followed by a deprotection–cyclization step to provide fast entry into two biologically enticing imidazoquinoxaline families. For the first time ethyl glyoxylate and benzyl glyoxamide were employed in the V-3CR, resulting in an extension of the scope of this condensation. With high operational ease and the capability of furnishing target structures **8** and **11** with two diversity points, this route appears superior to the existing lengthy multistep pathways toward such chemotypes. Thanks to the advantages outlined above, our strategy is highly amenable for high-throughput applications and will hopefully represent a valuable new tool available for the lead generation community.

Acknowledgments

Financial support from the National Institutes of Health (Grant P41GM086190) is gratefully acknowledged. We also thank Dr. Federico Medda and Dr. David Bishop for proofreading and editing the final version of the manuscript.

References

1. Van Leusen, D.; Van Leusen, AM. Synthetic Uses of Tosylmethyl Isocyanide (TOSMIC) in Organic Reactions. Overman, LE., editor. Wiley; Hoboken, New Jersey: 2004. p. 417-666.
2. Van Leusen AM, Wildeman J, Oldenzil OH. J Org Chem. 1977; 42:1153.
3. (a) Wu B, Wen J, Zhang J, Li J, Xiang YZ, Yu XQ. Synlett. 2009; 3:500.(b) Chakrabarty M, Basak R, Harigaya Y, Takayanagi H. Tetrahedron. 2005; 61:1793.(c) Atkins JM, Vedejs E. Org Lett. 2005; 7:3351. [PubMed: 16018658] (d) Kotha S, Shah VR. Synthesis. 2007:3653.
4. (a) Kelly JM, Leeper FJ. Tetrahedron Lett. 2012; 53:819.(b) Qiu F, Wu J, Zhang Y, Hu M, Yu Y. Tetrahedron Lett. 2012; 53:446.(c) Sanchez-Garcia D, Borrell JI, Nonell S. Org Lett. 2009; 11:77. [PubMed: 19053828] (d) Clayden J, Turnbull R, Pinto I. Org Lett. 2004; 6:609. [PubMed: 14961635]

5. (a) Dömling A, Beck B, Herdtweck E, Antuch W, Oefner C, Yehia N, Gracia-Marques A. ARKIVOC. 2007; 12:99.(b) Srivastava S, Wang W, Czarna A, Holak TA, Dömling A. J Comb Chem. 2009; 11:631. [PubMed: 19548636]
6. Garcia-González C, González-Zamora E, Satilla R, Farfán N. Synlett. 2011; 3:308.
7. Neochoritis C, Stephanidou-Stephanatou J, Tsoleridis CA. Synlett. 2009; 2:302.
8. Mendiola J, Baeza A, Alvarez-Builla J, Vaquero JJ. J Org Chem. 2003; 69:4974. [PubMed: 15255724]
9. For exhaustive overviews on this topic see: Multicomponent Reactions. Zhu J, Bienaymé H. Wiley-VCH Weinheim: Germany 2005 Dömling A. Chem Rev. 2006; 106:17. [PubMed: 16402771] Dömling A, Wang W, Wang K. Chem Rev. 2012; 112:3083. [PubMed: 22435608] Ruijter E, Scheffelaar R, Orru RVA. Angew Chem, Int Ed. 2011; 50:6234. Sunderhaus JD, Martin SE. Chem Eur J. 2009; 15:1300. [PubMed: 19132705] Hulme C, Dietrich J. Mol Diversity. 2009; 13:195.
10. For applications of imidazoles in medicinal chemistry see: De Luca L. Curr Med Chem. 2006; 13:1. [PubMed: 16457636] Boiani M, Gonzalez M. Mini-Rev Med Chem. 2005; 5:68.
11. See for example: Antuch W, Menon S, Chen QZ, Lu Y, Sakamuri S, Beck B, Schauer-Vukasinovi V, Agarwal S, Hess S, Dömling A. Bioorg Med Chem Lett. 2006; 16:1740. [PubMed: 16427279] Beck B, Leppert CA, Mueller BK, Dömling A. QSAR Comb Sci. 2006; 5:127.
12. (a) Gracias V, Gasiński AF, Djuric SW. Tetrahedron Lett. 2005; 46:9049.(b) Gracias V, Darczak D, Gasiński AF, Djuric SW. Tetrahedron Lett. 2005; 46:9053.(c) Gracias V, Gasiński AF, Pagano TG, Djuric SW. Tetrahedron Lett. 2006; 47:8873.(d) Beebe X, Gracias V, Djuric SW. Tetrahedron Lett. 2006; 47:3225.
13. For reviews describing the post-condensation modification approach see: Banfi L, Riva R, Basso A. Synlett. 2010; 1:23. Basso A, Banfi L, Riva R. Eur J Org Chem. 2010:1831.
14. (a) Bon RS, Hong C, Bouma MJ, Schmitz RF, De Kanter FJJ, Lutz M, Spek AL, Orru RVA. Org Lett. 2003; 5:3759. [PubMed: 14507224] (b) Elders N, Schmitz RF, Ruijter E, Groen MB, Orru RVA. J Org Chem. 2007; 72:6135. [PubMed: 17628108] (c) Bon RS, Sprenkels NE, Koningstein MM, Schmitz RF, De Kanter FJJ, Dömling A, Orru RVA. Org Biomol Chem. 2008; 6:130. [PubMed: 18075657]
15. For recent examples see: Gunawan S, Petit J, Hulme C. ACS Comb Sci. 2012; 14:160. [PubMed: 22330239] Shaw AY, Medda F, Hulme C. Tetrahedron Lett. 2012; 53:1313. [PubMed: 22368307] Gunawan S, Ayaz M, De Moliner F, Frett B, Kaiser C, Patrick N, Zu X, Hulme C. Tetrahedron. 2012; 68:5606. [PubMed: 22923851] Gunawan S, Keck K, Laetsch A, Hulme C. Mol Divers. 2012 <http://dx.doi.org/10.1007/s11030-012-9373-2>
16. De Moliner F, Hulme C. Org Lett. 2012; 14:1354. [PubMed: 22356134]
17. *General procedure exemplified for the preparation of 8c*: Ethyl glyoxylate (1.5 equiv, 0.72 mmol, 173 μ L of a 50% soln. in toluene) and *tert*-butyl (2- amino-4,5-dimethylphenyl)carbamate (1 equiv, 0.48 mmol, 113 mg) were dissolved in DMF (2 mL) and heated at 100 °C for 10 min by means of microwave irradiation. Potassium carbonate (2 equiv, 0.96 mmol, 132 mg) and methyl-TOSMIC (1 equiv, 0.48 mmol, 100 mg) were then added, and the reaction mixture was heated at 180 °C for 10 min. After cooling to room temperature, water (20 mL) was added and extraction with EtOAc (3 $\times$ 20 mL) was performed. The organic phase was dried over MgSO₄ and concentrated under reduced pressure, and the crude was purified by flash chromatography (EtOAc/Hexane 50–100%) using an ISCO™ purification system to afford 3,7,8-trimethylimidazo[1,5-*a*]quinoxalin-4(5*H*)-one **8c** as a yellow solid (44 mg, 40% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 11.02 (s, 1H), 8.75 (s, 1H), 7.87 (s, 1H), 6.98 (s, 1H), 2.52 (s, 3H), 2.23 (s, 3H), 2.20 (s, 3H) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 156.2, 142.2, 135.6, 131.4, 128.2, 127.2, 118.8, 117.3, 116.3, 109.9, 19.7, 19.5, 14.5 ppm.
18. (a) Campbell, SF.; Mackenzie, AR.; Wood, A. WO. 96/16644. 1996. (b) Kim K-H, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J, Wrocklage C, Nickerson-Nutter CL, Wittwer AJ, Soutter H, Caspers N, Han S, Kurumbail R, Dunussi-Joannopoulos K, Douhan J, Wissner A III. Bioorg Med Chem Lett. 2011; 21:6258. [PubMed: 21958547] (c) Stockman BJ, Kothe M, Kohls D, Weibley L, Connolly BJ, Sheils AL, Cao Q, Cheng AC, Yang L, Kamath AV, Ding Y-H, Charlton ME. Chem Biol Drug Des. 2009; 73:179. [PubMed: 19207420]

19. (a) Barrish, JC.; Chen, P.; Das, J.; Iwanowicz, EJ.; Norris, DJ.; Padmanabha, R.; Roberge, JY.; Schieven, GL. WO. 99/09845. 1999. (b) Chen P, Norris D, Iwanowicz EJ, Spergel SH, Lin J, Gu HH, Shen Z, Witjak J, Lin T-A, Pang S, De Fex HF, Pitt S, Shen DR, Doweiko AM, Bassolino DA, Roberge JY, Poss MA, Chen B-C, Schieven GL, Barrish JC. Bioorg Med Chem Lett. 2002; 12:1361. [PubMed: 11992777] (c) Moarbess G, Deleuze-Masquefa C, Bonnard V, Gayraud-Paniagua S, Vidal JR, Bressolle F, Pinguet F, Bonnet PA. Bioorg Med Chem Lett. 2008; 16:6601.
20. Petasis, NA.; Yao, X. US Patent. 0010162. 2004.
21. *General procedure exemplified for the preparation of 10e.* Benzylglyoxamide (1 equiv, 0.48 mmol, 78 mg) and *tert*-butyl (2-aminophenyl)carbamate (1 equiv, 0.48 mmol, 100 mg) were dissolved in DMF (2 mL) and heated at 100 °C for 10 min by means of microwave irradiation. Potassium carbonate (2 equiv, 0.96 mmol, 132 mg) and ethyl-TOSMIC (1 equiv, 0.48 mmol, 107 mg) were then added, and the reaction mixture was stirred overnight at room temperature. Water (20 mL) was added and extraction with EtOAc (3 × 20 mL) was performed. The organic phase was dried over MgSO₄ and concentrated under reduced pressure, and the crude was purified by flash chromatography (EtOAc/hexane 50–100%) using an ISCOTM purification system to afford *tert*-butyl (2-(5-(benzylcarbamoyl)-4-ethyl-1*H*-imidazol-1-yl)phenyl)carbamate **10e** as an orange oil (138 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃) δ: 7.85–7.80 (m, 1H), 7.45 (s, 1H), 7.43–7.37 (m, 1H), 7.28–7.21 (m, 3H), 7.15–7.11 (m, 2H), 7.09–7.03 (m, 2H), 6.53 (s, 1H), 6.30 (s, 1H), 4.47–4.35 (m, 2H), 2.88 (q, *J* = 7.5 Hz, 2H), 1.41 (s, 9H), 1.33 (t, *J* = 7.6 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ: 160.2, 152.9, 148.2, 139.0, 137.6, 134.4, 130.1, 128.6, 128.5, 127.9, 127.5, 127.4, 125.0, 124.9, 123.9, 123.7, 123.2, 81.4, 43.5, 28.1, 21.7, 13.8 ppm.
22. *General procedure exemplified for the preparation of 11e.* *tert*-Butyl (2-(5-(benzylcarbamoyl)-4-ethyl-1*H*-imidazol-1-yl)phenyl)carbamate **10e** (1 equiv, 0.29 mmol, 120 mg) was dissolved in 3 mL of a 10% TFA/DCE solution and heated at 120 °C for 10 min by means of microwave irradiation. After cooling to room temperature, the reaction mixture was diluted with NaHCO₃ sat. solution (20 mL) and extraction with EtOAc (3 × 20 mL) was performed. The organic phase was dried over MgSO₄ and concentrated under reduced pressure to afford **11e** as a pink powder (55 mg, 91% yield) with no need of purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 11.13 (br s, 2H), 8.87 (s, 1H), 8.09 (dd, *J* = 8.2, 1.1 Hz, 1H), 7.33–7.23 (m, 2H), 7.21–7.14 (m, 1H), 2.97 (q, *J* = 7.5 Hz, 2H), 1.21 (t, *J* = 7.5 Hz, 3H) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 156.0, 148.2, 131.8, 129.4, 129.0, 127.3, 123.1, 120.9, 116.9, 115.9, 21.4, 14.4 ppm.
23. (a) Colotta V, Cecchi L, Catarzi D, Filacchioni G, Martini C, Tacchi P, Lucacchini A. Eur J Med Chem. 1995; 30:133. (b) Hoefgen, N.; Stange, S.; Langen, B.; Egerlan, U.; Schindler, R. WO. 09/068320. 2009. (c) Malamas, MS.; Ni, Y.; Erdei, JJ.; Stange, S.; Schindler, R.; Hoefgen, N.; Egerlan, U.; Langen, B. WO. 09/070584. 2009.

Figure 1.

Compounds **8a–8g** synthesized from ethyl glyoxylate, *N*-Boc 1,2-phenylenediamines, and TOSMICs.

Figure 2.

Compounds **11a–11g** synthesized from ethyl glyoxylate, *N*-Boc 1,2-phenylenediamines, and TOSMICs (X%, X% = Van Leusen yield, deprotection-cyclization yield).

Scheme 1.
Mechanism of the Van Leusen three-component reaction (V-3CR).

Table 1

Optimization of the one-pot Van Leusen cyclization protocol involving ethyl glyoxylate

Entry	Solvent	Conditions (Step A)	Conditions (Step B)	Yield (%)
1	DMF	MW (5 min, 100 °C)	MW (10 min, 140 °C)	30
2	DMF	MW (5 min, 100 °C)	MW (10 min, 160 °C)	35
3	DMF	MW (5 min, 100 °C)	MW (10 min, 180 °C)	41
4	DMF	MW (10 min, 100 °C)	MW (10 min, 180 °C)	47
5	DMF	MW (20 min, 120 °C)	MW (10 min, 180 °C)	38
6	DMF	MW (10 min, 100 °C)	MW (20 min, 180 °C)	45
7	DMF	MW (10 min, 100 °C)	MW (10 min, 200 °C)	39

Table 2

Optimization of the Van Leusen reaction involving benzylglyoxamide

Entry	Solvent	Conditions (Step A)	Conditions (Step B)	Yield (%)
1	DMF	MW (10 min, 100 °C)	MW (10 min, 180 °C)	—
2	DMF	MW (10 min, 100 °C)	MW (10 min, 160 °C)	—
3	DMF	MW (10 min, 100 °C)	MW (10 min, 140 °C)	63
4	DMF	MW (10 min, 100 °C)	MW (10 min, 120 °C)	63
5	DMF	MW (10 min, 100 °C)	MW (10 min, 100 °C)	62
6	DMF	MW (10 min, 100 °C)	MW (10 min, 80 °C)	73
7	DMF	MW (10 min, 100 °C)	rt, overnight	83
8	DMF	MW (5 min, 100 °C)	rt, overnight	75
9	DMF	MW (20 min, 120 °C)	rt, overnight	60

Table 3

Optimization of the double deprotection-cyclization step

Entry	Time	Temperature	Yield (%)
1	Overnight	rt	87
2	10 min	60 °C (MW)	80
3	10 min	80 °C (MW)	85
4	10 min	100 °C (MW)	85
5	10 min	120 °C (MW)	88
6	10 min	140 °C (MW)	74